More recently, a post hoc analysis of the CHECKMATE025 trial which compared nivolumab and sunitinib in ccRCC patients previously treated with antiangiogenics, analyzed the correlation between PBRM1 status and outcomes (PFS and OS) across-treatment in 382 of the 803 patients included in the trial [58]. This evidence concerns the gene PBRM1 and nonpapillary renal cell carcinoma.